Febrile Neutropenia Biosimilar Provides Clinical and Economic Value

April 19, 2022

An analysis published in Future Oncology found that the biosimilar pegfilgrastim (PEG) can reduce spending in patients with febrile neutropenia (FN) as primary prophylaxis in high-risk patients with cancer. Around 60,000 patients are hospitalized with FN, with each admission costing ~$28,000. Authors of the study report that PEG reduced hospital admissions for FN, which typically causes cause delays in chemotherapy regimens that reduce survival rates.

According to Laura Joszt, “ Probabilistic sensitivity analyses determined the probability of PEG biosimilar being cost-effective compared with FIL biosimilar at a willingness-to-pay threshold of $100,000 per QALY gained, per LY gained, and per FN event avoided to be 100%, 100%, and 100%.”

Click here to read more.

(Source: AJMC, April 18th, 2022)

Share This Story!